Financials

Discussions Technicals Seasonals

6580 fundamentals

Overview Statements Statistics Dividends Earnings Revenue

Key facts

—

—

—

—

—

—

—

—

About

TaiRx, Inc. engages in the research and development of novel drug products for cancer treatment. Its products include CVM-118, Rexis, Zelnite, TRX-711, TRX-NOC, TRX-920, and TRX-105. The company was founded by Du Shieng Chien and Yi Wen Chu on August 22, 2011 and is headquartered in Taipei, Taiwan.

Valuation

Fundamental metrics to determine fair value of the stock

Summary

No data available

There's currently no market capitalization, revenue or net income data to show.

Valuation ratios

Growth and Profitability

Company’s recent performance and margins

Dividends

Dividend yield, history and sustainability

6580 does not pay dividends

The company has not previously paid dividends and at the moment there is no information about whether it is going to pay them in the future

Financial health

Financial position and solvency of the company